Citigroup’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Citigroup’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-85,757	Closed	-$9.2M	–	5834
2023 Q1	$9.2M	Buy	85,757 +52,077	+155%	+$5.99M	0.01%	1200
2022 Q4	$3.7M	Sell	33,680 -53,685	-61%	-$3.48M	﹤0.01%	1640
2022 Q3	$5.16M	Buy	87,365 +84,584	+3,041%	+$3.87M	﹤0.01%	1550
2022 Q2	$78K	Sell	2,781 -6,501	-70%	-$188K	﹤0.01%	4344
2022 Q1	$350K	Buy	9,282 +285	+3%	+$11.3K	﹤0.01%	3744
2021 Q4	$356K	Buy	8,997 +7,707	+597%	+$241K	﹤0.01%	4021
2021 Q3	$31K	Buy	1,290 +753	+140%	+$17.8K	﹤0.01%	5017
2021 Q2	$13K	Buy	+537	New	+$12K	﹤0.01%	5552

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Citigroup's RXDX Position: Q2 2023 in Review

Citigroup sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 85,757 shares — an estimated $9.2M sold.

Citigroup first reported a position in RXDX in Q2 2021 and held it in 8 quarters. The position peaked at $9.2M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Citigroup reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Citigroup sold 85,757 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $9.2M.
Citigroup first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Citigroup's Prometheus Biosciences, Inc. Common Stock position peaked at $9.2M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Citigroup's 13F filing for Q2 2023, filed 10 Aug 2023.